• BioCorRx posted a net loss of USD 859,892 for the quarter ended March 31, 2026, while net loss attributable to shareholders narrowed to USD 831,227.
• Revenue rose 59% to USD 214,539, driven by Lucemyra distribution sales, with supply and distribution net sales of USD 213,209.
• Total operating expenses increased to USD 1.17 million, led by higher research and development spending of USD 352,333.
• Cash totaled USD 211,911, with net cash used in operating activities of USD 432,971.
• BioCorRx increased its ownership in BioCorRx Pharmaceuticals by 12.15% via a stock exchange that issued 2,263,371 common shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-003159), on May 15, 2026, and is solely responsible for the information contained therein.